



Molecular Targeting Technologies, Inc. Development Pipeline

CLASS: Therapeutic

NAME: Rabies mAb

INDICATION: Rabies

USES: treatment of rabies in humans

TECHNOLOGY: Current post exposure prophylaxis rabies treatment requires multiple injections of vaccine with rabies immunoglobulin. Research shows that an mAb virus clone expresses innate immune molecules that enhances adaptive immune responses to conventional vaccine treatment.

UNMET NEED: Thanks to prophylaxis and veterinary vaccination, The US experiences 1-2 rabies deaths per year. The CDC and WHO report a much larger, probably underreported, prevalence in developing countries. China has seen >3000 deaths from >20,000 reported rabies cases in the last decade. Though decreasing slowly, the Chinese government launched an initiative to counter this trend and develop viable, efficient treatments. Defined as a “neglected tropical disease,” 17,500 deaths are reported globally, annually. 95% in Africa, Asia and Latin America.

PROOF OF CONCEPT:

Completed IIa clinical trial (rhRIG and HRIG comparison test, 60 patients) and IIb trials (rhRIG and vaccine combined with vaccines and HRIG and combined with the comparison test, 200 patients).

North China Pharmaceutical Company (NCPC) is initiating the phase III clinical trial in China in 2018.

STAGE OF DEVELOPMENT: Entering Phase III development in 2018

PARTNER : MTTI sublicensed the product to North China Pharmaceutical Company in exchange for future royalty stream. NCPC is responsible for all clinical development costs.

IP: MTTI licensed from the Thomas Jefferson University

FUNDING: \$425,000 from USDA (2006); \$918,000 from NIH (2007).

OWNERSHIP: MTTI shares co-exclusive rights in China with Johnson & Johnson (previously Crucell)